Podcasts about biotech

Use of living systems and organisms to develop or make useful products

  • 2,983PODCASTS
  • 8,819EPISODES
  • 38mAVG DURATION
  • 2DAILY NEW EPISODES
  • Sep 9, 2025LATEST
biotech

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about biotech

Show all podcasts related to biotech

Latest podcast episodes about biotech

The John Batchelor Show
Michael Sobolik. China's Biowarfare Ambitions Threaten US Dominance and Global Health. China's Communist Party develops biowarfare, including ethnic-specific genetic attacks, to achieve strategic dominance over the US. China aims to divert US biotech in

The John Batchelor Show

Play Episode Listen Later Sep 9, 2025 9:00


Michael Sobolik.Gordon Chang. China's Biowarfare Ambitions Threaten US Dominance and Global Health. China's Communist Party develops biowarfare, including ethnic-specific genetic attacks, to achieve strategic dominance over the US. China aims to divert US biotech innovation and control future vaccine distribution, leveraging lessons from COVID-19. US vaccine hesitancy and decreased investment in cutting-edge technology leave it dangerously exposed to future biothreats. 1906 PEKING DRUM TOWER

OffScrip with Matthew Zachary
Building Tools, Not Excuses: Rethinking Healthcare with Marc Elia

OffScrip with Matthew Zachary

Play Episode Listen Later Sep 9, 2025 37:45


This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pharma and BioTech Daily
Pharma and Biotech Daily: Top News in the World of Healthcare

Pharma and BioTech Daily

Play Episode Listen Later Sep 9, 2025 1:37


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.A new data release shows that Summit's Keytruda competitor, Ivonescimab, had better overall survival rates in Asian patients compared to those in North America and Europe. Despite this, the drug narrowly missed the statistical significance threshold required by the FDA for approval in Western countries. Meanwhile, Rapport Therapeutics saw a 180% increase in its stock value after positive mid-stage data for its epilepsy pill, and the FDA opted for a consumer "green list" instead of addressing compounded versions of obesity drugs. The FDA's leadership turnover has led to confusion and uncertainty for small and medium biopharma companies. Lilly is seeking individuals who are willing to challenge the status quo in medicine.FDA expert panels are being criticized for lack of balance, with some meetings being one-sided. RFK Jr. faced bipartisan criticism for his anti-vaccine views during a Senate hearing. Meanwhile, Servier committed up to $530 million in an eye cancer deal and Gilead partnered with the US State Department to distribute a drug to low-income countries. The FDA released a new rare disease approval framework and dropped heavily redacted rejection letters. Amidst uncertainty in FDA leadership, small and medium biopharma companies are left without clear guidance for their therapies. Opinion pieces highlight the potential of small molecules in gene therapy for Duchenne muscular dystrophy and criticize the lack of balance in FDA expert panels. The newsletter also includes upcoming events, job listings, and a request for feedback on coverage topics.

Inside the ICE House
Biotech Series: Nimbus CEO Abbas Kazimi on Leading the Future of Precision Therapeutics

Inside the ICE House

Play Episode Listen Later Sep 8, 2025 26:26


Nimbus Therapeutics is transforming drug discovery with computational chemistry and AI to design small molecules that precisely target disease. CEO Abbas Kazimi, who took the helm in March, is driving a “fail fast” approach that balances discipline with innovation. He joins Inside the ICE House to share how Nimbus is scaling its pipeline and shaping the future of precision medicine.

Business Of Biotech
Investing In The Biostack With Modi Ventures' Sahir Ali, Ph.D.

Business Of Biotech

Play Episode Listen Later Sep 8, 2025 57:54 Transcription Available


We love to hear from our listeners. Send us a message. On the Business of Biotech this week, Sahir Ali, Ph.D., founder and general partner at Modi Ventures, a family office investing at the intersection of technology and biology, talks about adapting the Markowitz model to improve returns and balance risk, his concept of the "biostack" for making direct investments into life sciences companies, and the revolutionary potential of scientific super intelligence. Ali explains why Houston, Texas is an underrated ecosystem for life sciences, and what AI will mean for medicine and the future of healthcare consumption.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Pharma and BioTech Daily
Pharma and Biotech Daily: Kennedy Faces Criticism, FDA Rejections, and Industry Deals

Pharma and BioTech Daily

Play Episode Listen Later Sep 8, 2025 0:56


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. During a Senate hearing, Robert F. Kennedy Jr. faced criticism for spreading anti-vaccine views and breaking promises regarding vaccines. The FDA released rejection letters for companies like Lykos Therapeutics, Stealth Biotherapeutics, and Regeneron. Ousted CDC director Susan Monarez accused Kennedy of firing her for not supporting Covid-19 recommendations from an advisory panel with "antivaccine rhetoric." Hengrui Pharmaceuticals signed lucrative deals with Merck and GSK, while the FDA promised to release future Complete Response Letters promptly. In other news, Sanofi's anti-OX40 blocker failed in a Phase III study, Gilead partnered with the US State Department for low-income countries, and AC Immune announced workforce cuts. Kennedy was accused of lying during the hearing, and the FDA released a new rare disease approval framework.

GZero World with Ian Bremmer
How AI will revolutionize medicine with Siddhartha Mukherjee

GZero World with Ian Bremmer

Play Episode Listen Later Sep 6, 2025 33:04


On the latest episode of the GZERO World podcast, Ian Bremmer talks with world-renowned cancer researcher and Pulitzer Prize-winning author Siddhartha Mukherjee about the future of medicine—and why artificial intelligence might finally tip the scales in the decades-long war on cancer.Cancer remains the second leading cause of death in the US, killing nearly 1,700 people every day. But Mukherjee says AI is already reshaping the field, from radiology and diagnostics to identifying new carcinogens and designing entirely new cancer drugs. “Every time we do this in collaboration with a machine,” he explains, “the machine learns it, and it learns it forever.”In a wide-ranging conversation, Mukherjee breaks down three major areas where AI is advancing medicine: patient care, data mining, and generative drug development. He also weighs in on early cancer detection, how inflammation may hold the key to understanding new carcinogens, and why this moment may be the most hopeful in half a century of cancer research.Host: Ian BremmerGuest: Siddhartha Mukherjee Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

GZERO World with Ian Bremmer
How AI will revolutionize medicine with Siddhartha Mukherjee

GZERO World with Ian Bremmer

Play Episode Listen Later Sep 6, 2025 33:04


On the latest episode of the GZERO World podcast, Ian Bremmer talks with world-renowned cancer researcher and Pulitzer Prize-winning author Siddhartha Mukherjee about the future of medicine—and why artificial intelligence might finally tip the scales in the decades-long war on cancer.Cancer remains the second leading cause of death in the US, killing nearly 1,700 people every day. But Mukherjee says AI is already reshaping the field, from radiology and diagnostics to identifying new carcinogens and designing entirely new cancer drugs. “Every time we do this in collaboration with a machine,” he explains, “the machine learns it, and it learns it forever.”In a wide-ranging conversation, Mukherjee breaks down three major areas where AI is advancing medicine: patient care, data mining, and generative drug development. He also weighs in on early cancer detection, how inflammation may hold the key to understanding new carcinogens, and why this moment may be the most hopeful in half a century of cancer research.Host: Ian BremmerGuest: Siddhartha Mukherjee Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

The Weekly Trend
Episode 267: All Over The Place

The Weekly Trend

Play Episode Listen Later Sep 5, 2025 29:56


 In this week's episode, David and Ian discuss how precious metals and precious metals miners continue to do well, homebuilders are showing strength, lumber continuing to move lower, whether this is a start of a larger move in Biotech, areas of strength within small caps, moves in interest rates, and other areas of the market that are consolidating.  

Pharma and BioTech Daily
Senate Hearings, Vaccine Advisors, and FDA Approvals: The Latest in Pharma and Biotech

Pharma and BioTech Daily

Play Episode Listen Later Sep 5, 2025 0:49


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Robert F. Kennedy Jr. faced the Senate Finance Committee in a tense hearing amidst calls for the removal of the health secretary. The committee questioned Kennedy on his recent actions, including the firing of CDC director Susan Monarez. Meanwhile, the FDA's new rare disease pathway received mixed reactions, with some questioning its tangible impacts. AC Immune downsized and refocused its pipeline, while Kennedy proposed adding seven new vaccine advisors to the ACIP. Other news included successful RNA editing in an AATD study, demands for YouTube to remove anti-vaccine videos, and a new framework for rare disease approvals by the FDA. Thank you for tuning in to today's episode of Pharma and Biotech daily.

pharmaphorum Podcast
The glimmer of opportunity behind the storm: Ali Pashazadeh talks biotech investment

pharmaphorum Podcast

Play Episode Listen Later Sep 5, 2025 26:11


Biotech finance has encountered what can arguably be termed the worst perfect storm in its history, and private investment in biopharma is in the midst of the longest drought. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, a strategic and financial advisory firm for the life sciences sector, in a conversation focused on the current ‘perfect storm' in biotech and why the skies might not be quite as grey and foreboding as at first feared. Pashazadeh discusses how developers, CDMOs, CROs, and all other companies involved in therapeutic development might have to adjust to this new world. You can also listen to episode 203a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

The Business of Aquaculture
From Operating Rooms to Ocean Farms: Biotech Innovation for Aquaculture with Craig Ingram

The Business of Aquaculture

Play Episode Listen Later Sep 5, 2025 20:50


In this episode of The Business of Aquaculture, we dive deep into the intersection of health-tech and aquaculture with biotech veteran Craig Ingram, founder of Int'l Commercialization Growth Partners. With 27 years of experience spanning medical devices, biopharma, and digital health—beginning at just 19—Craig now helps VC-backed startups and SMEs scale by boosting customer adoption and preventing costly shutdowns.We explore:How innovations from surgical systems and biotech—like biosensors and sterilization protocols—can revolutionize aquaculture biosecurity.The untapped crossover potential between medical-grade technologies and sustainable food systems.Why precision health management is the next frontier in aquaculture, and how biotech is paving the way for smarter, cleaner marine operations.Tune in for a boundary-crossing conversation that connects operating rooms to ocean farms, and learn how biotech's cutting edge could become aquaculture's new baseline.Support the show

Beyond Biotech - the podcast from Labiotech
Navigating the biotech development journey from first steps to global scale with Lonza

Beyond Biotech - the podcast from Labiotech

Play Episode Listen Later Sep 5, 2025 50:40


Lonza is one of the world's largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from emerging biotechs to top global pharmaceutical companies – to transform therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Founded in 1897 in the Swiss Alps, Lonza has embraced innovation and kept pace with a fast-changing world for more than 125 years. They are a leader in both established and emerging technologies and today their 19,000 employees across more than 30 sites on five continents generate annual sales of more than $4.4 billion. We sat down with Alice Harrison, Global Technical Director (CMC and Analytics), and Megan Mason, Global Process Development Implementation Manager, to learn more about how Lonza is helping innovators large and small develop and scale their therapies and deliver better outcomes for patients worldwide._____The information in this podcast is believed to be correct at the time of recording, and is for information only. While we make reasonable efforts to ensure that the content is accurate, we make no representations or warranties of any kind regarding its accuracy, completeness, reliability, suitability or the results to be obtained from the use of such information. Lonza disclaims any liability for the use of this information and the reliance of the information contained herein is at your own risk.  _____Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: How to Set up Manufacturing for Biotech StartupsAccelerating the path to clinical filing applications with rapid toxicology material deliveryLarge molecule manufacturing: addressing challenges with strategies for success

Inside the ICE House
Biotech Series: Eli Lilly Chief AI Officer Thomas Fuchs on AI's Power to Transform Pharmaceuticals

Inside the ICE House

Play Episode Listen Later Sep 4, 2025 24:30


AI is revolutionizing pharmaceuticals, moving from a side tool to a core driver of many aspects of the industry. Eli Lilly is leading the way, appointing Thomas Fuchs as its first Chief AI Officer to integrate AI across its pipeline. A NASA and Mount Sinai veteran, Fuchs is turning Lilly's data into a competitive edge. He joins Inside the ICE House to share how Lilly is building the AI-powered medicine company of the future.

Smart Biotech Scientist | Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists
186: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de Reus - Part 2

Smart Biotech Scientist | Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

Play Episode Listen Later Sep 4, 2025 15:49


Imagine unlocking a world where designing custom proteins is not only feasible - but faster, smarter, and more powerful than ever before, thanks to artificial intelligence.As the promise of programmable biology takes center stage, AI-driven protein engineering is rapidly moving from theoretical dream to industry standard.In this episode, David Brühlmann sits down with Elise de Reus, co-founder of Cradle, whose ground-breaking platform has become a go-to for luminaries at pharma giants, as well as leaders in agriculture and industrial biotech. Elise's journey bridges hands-on scientific discovery with entrepreneurial vision, and she's on a mission to make biology a foundational pillar of a more sustainable and equitable world.Here are three reasons you can't miss this episode:AI Unmasks the Black Box: Elise explains how Cradle's platform isn't just about predictive power - it offers transparency and actionable insights, allowing scientists to see why models perform as they do, and how to interpret and trust their outputs.From Hype to Real-World Impact: You'll hear real examples of AI accelerating everything from pandemic preparedness and antivenom development, to sustainable raw materials - plus candid advice on scaling AI adoption across diverse project teams.Blueprints for Biotech Founders: Elise shares hard-won lessons on transforming scientific innovation into a thriving company, including the counterintuitive power of targeting “mission impossible” challenges and the priceless value of early, unfiltered feedback.Ready to future-proof your protein engineering with generative AI? Press play to take home Elise's practical framework for evaluating tools, overcoming organizational hurdles, and crafting a winning adoption strategy, before the innovation curve pulls away.Wondering how Generative AI is transforming the biotech landscape? From accelerating regulatory workflows to reinventing protein purification, AI is driving breakthroughs across the industry. Explore these standout episodes to hear from experts leading the charge:Episodes 77-78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro TorresEpisodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian GuoEpisodes 123-124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 167-168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet SatwekarConnect with Elise de Reus:LinkedIn: www.linkedin.com/in/elise-de-reus-77b83a24Website: www.cradle.bioNext step:Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Pharma and BioTech Daily
Bioscience Buzz: The Latest in Pharma and Biotech Advancements

Pharma and BioTech Daily

Play Episode Listen Later Sep 4, 2025 1:18


Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis has increased its commitment to its partnership with Argo BioPharma by an additional $5.2 billion, focusing on RNAi agreements targeting cardiovascular diseases. This highlights the ongoing advancements and challenges in the biopharmaceutical industry. Biotechs are turning to special purpose acquisition companies (SPACs) as a way to go public amid the IPO freeze. Gene therapy, with its potential to cure deadly diseases, is still facing challenges in terms of insurance coverage in the U.S. The industry is seeing a shift with some of the biggest biotech SPACs from the 2021 bubble no longer on the market. Meanwhile, Cytokinetics' cardiac myosin inhibitor, aficamten, has shown promising results in a phase III study for patients with obstructive hypertrophic cardiomyopathy. RFK Jr. has announced plans to reorganize chronic disease programs in the US to address high COVID-19 death rates. Companies like Novartis and Arrowhead are making significant commitments to various programs, while Trump's efforts to shore up the pharma supply chain with U.S. API are being questioned. Novartis continues its cutting spree with layoffs in New Jersey.These developments shed light on the evolving landscape of the biopharmaceutical industry.

Data in Biotech
Inside Merck's Computational Biology Approach with Jesper Ryge

Data in Biotech

Play Episode Listen Later Sep 3, 2025 46:33


In this episode of Data in Biotech, host Ross Katz talks with Jesper Ryge, Director of Computational Biology at Merck Germany. Jesper shares his journey from neuroscience labs to leading computational teams, offering deep insights into disease modeling, target discovery, and multi-omics integration. Discover how AI and spatial transcriptomics are shaping the future of pharma R&D. ​​What You'll Learn in This Episode >> How single-cell and spatial transcriptomics enhance disease mechanism discovery >> Why data integration and knowledge graphs are critical for target validation >> How computational biology teams interface with wet lab research >> What makes Merck Germany's data strategy unique in biotech >> How generative AI is changing how pharma interprets complex datasets Meet Our Guest Jesper Ryge is Director of Computational Biology at Merck Germany. A biophysicist by training, he brings deep expertise in neuroscience, single-cell analysis, and bioinformatics to pharmaceutical R&D. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about MerckConnect with Jesper Ryge on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Bio from the Bayou
Episode 102: Building Patient-Centered Biotech Deals for a Stronger Future in Healthcare

Bio from the Bayou

Play Episode Listen Later Sep 3, 2025


How can healthcare investment banking put patients—not just profits—at the center of biotech deals? In this episode, host James Zanewicz, JD, LLM, RTTP, speaks with Sam Libby, President and Managing Director of TCB Capital Advisors. Drawing from more than $20 billion in transactions across therapeutics, diagnostics, and digital health, Sam explains how TCB's unique advisory model partners with companies before and after deals close. From growing up with therapist parents to founding a merchant bank, Sam shares how personal values and professional experience can come together to shape smarter strategies for healthcare innovation. In this episode, you'll learn: Why patient-centered thinking belongs at the core of investment strategy. Common mistakes healthcare startups make when pitching to investors—and how to avoid them. The critical role of clinical data, mission alignment, and timing in building sustainable biotech companies. Tune in to learn how to navigate healthcare investments with purpose and ensure your biotech mission makes a lasting impact. Links: Connect with Sam Libby, and check out TCB Capital Advisors. Connect with James Zanewicz, JD, LLM, RTTP and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about Clairity and Informuta. Listen to our previous episode on Drug Pricing and Accessibility. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Pharma and BioTech Daily
Pharma and Biotech Daily: Navigating Innovation and Partnerships in Turbulent Times

Pharma and BioTech Daily

Play Episode Listen Later Sep 3, 2025 1:44


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has successfully reduced cardiovascular risk by 57% compared to tirzepatide. Eli Lilly has terminated two mid-stage trials for a second obesity asset, while Vertex Pharmaceuticals and Enlaza Therapeutics have formed a potential $2 billion partnership to develop drugs for autoimmune diseases. Biogen and Eisai have received FDA approval for the subcutaneous maintenance formulation of Leqvembi. Arrowhead Pharmaceuticals has secured a commitment of up to $2 billion from Novartis for an siRNA Parkinson's program. The FDA's new radiopharma guidance is expected to accelerate the space, and Teva has launched the first generic version of Novo Nordisk's obesity drug Saxenda. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies focusing on innovation and new partnerships to drive progress.The FDA has issued new radiopharma guidance, which former FDA Commissioner Stephen Hahn believes is crucial for cancer therapy. Despite recent investments in radiopharmaceutical therapeutics by big pharma, the FDA's approval of updated COVID-19 vaccines with restrictions contradicts the medical freedom promised by health secretary Robert F. Kennedy Jr. Rare diseases secured four FDA firsts in August, including a win for Novo Nordisk's glp-1 drug WeGovy. Investment in new ALS therapies signals progress after setbacks, with new biotechs and collaborative initiatives showing promise at Bio2025. Other news includes the closure of Appia, Senate summons of Kennedy, updates on COVID-19 vaccines, and Lilly's obesity pill heading to the FDA. Thank you for listening to Pharma and Biotech daily.

OffScrip with Matthew Zachary
LEAD EP5: Redemption

OffScrip with Matthew Zachary

Play Episode Listen Later Sep 2, 2025 23:56


After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Inside the ICE House
BioTech Series: Alto Neuroscience CEO Dr. Amit Etkin on the Next Chapter in Mental Health Treatment

Inside the ICE House

Play Episode Listen Later Sep 2, 2025 20:14


The future of mental health is being transformed, moving beyond trial-and-error treatments to science-driven precision. Breakthroughs in neuroscience, AI, and precision medicine are mapping the brain's unique biological signatures, creating pathways for personalized care. Alto Neuroscience is at the forefront, using brain biomarkers and AI to match patients with the right therapies—fast. Founded in 2019 by Dr. Amit Etkin, the company is rewriting the rules of mental health treatment. He goes Inside the ICE house to explain how Alto is turning guesswork into guided science and offering hope where it once felt out of reach.

Middle Tech
Parasight Systems: Eric Hauck on Building Biotech Hardware to Fight Parasites in Pets & Livestock

Middle Tech

Play Episode Listen Later Sep 2, 2025 73:36


In this episode, we sit down with Eric Hauck, founder and CEO of Parasight Systems, to explore how a biotech hardware startup based in Lexington is solving one of veterinary medicine's most overlooked problems: parasite resistance caused by overmedication. From pasture animals to household pets, Parasight is building AI-powered diagnostic machines that make fecal testing easy, accurate, and accessible—replacing outdated lab work with push-button automation.Expect to learn how SBIR matching grants brought Hauck to Kentucky and helped launch a scalable biotech business, why animal diagnostics is a $100B opportunity growing 8% annually, how Parasight uses 3D printing and machine learning to rapidly iterate and improve its hardware, and why Lexington's mix of research, funding, and quality of life makes it a rising hub for hard tech innovation.Middle Tech is proudly supported by:KY Innovation → kyinnovation.comAwesome Inc → awesomeinc.orgDon't miss Awesome Inc's September 5 Across → ⁠⁠⁠Free Ticket for Middle Tech listeners

Smart Biotech Scientist | Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists
185: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de Reus - Part 1

Smart Biotech Scientist | Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

Play Episode Listen Later Sep 2, 2025 22:51


For decades, protein design has hinged on painstaking rounds of wet lab mutagenesis and trial-and-error, a process limited not by human ingenuity, but by time and complexity. Yet as the biotech field seeks faster, greener, and more effective solutions for therapeutics and industrial applications, the next leap might not come solely from the lab bench.In this episode, host David Brühlmann explores the frontiers of AI-driven protein engineering with Elise de Reus, co-founder of Cradle. Elise's journey weaves together a passion for DNA, real-world impact from the dairy industry to synthetic biology, and high-throughput experience at Zymergen. Now, at the helm of Cradle, she is bridging cutting-edge computational models with experimental validation, making biology programmable and accelerating the path from idea to functional protein.Here are three reasons this episode is essential listening:AI Makes Biology Programmable: Generative AI platforms like Cradle can intelligently design protein variants by learning from evolutionary trends and your own project data, enabling smarter, faster iterations and optimizing for stability, activity, and manufacturability - simultaneously.Limited Data? No Problem: While traditional approaches have stumbled over small, “short and fat” datasets, new generative AI models can effectively update their understanding with as little as a 96-well plate per round, democratizing high-impact protein design for startups, academia, and industry alike.The Future is Human + Machine: Even as algorithms advance, Elise stresses the irreplaceable value of wet lab validation. Cradle's hybrid approach, integrating experimental feedback with algorithmic prediction, ensures reliable, scalable results and empowers multidisciplinary teams to unlock first- and best-in-class solutions.Want to see how you can leverage AI to simplify and accelerate your own protein engineering projects? Don't miss this episode to hear how Elise and Cradle are transforming the pace - and possibilities - of biotech.Curious how Generative AI is reshaping biotech? From streamlining regulatory compliance to transforming protein purification, AI is changing the game. Dive into these standout episodes to explore the cutting edge of innovation in biotech:Episodes 77-78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro TorresEpisodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian GuoEpisodes 123-124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 167-168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet SatwekarConnect with Elise de Reus:LinkedIn: www.linkedin.com/in/elise-de-reus-77b83a24Website: www.cradle.bioNext step:Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Sounds of Science
Off-Target, On-Point: How Retrogenix® Reduces Risk and Animal Use

Sounds of Science

Play Episode Listen Later Sep 2, 2025 28:05


In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA's ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O'Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.Show Notes Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening Paving the Way for Enhanced Drug Development A Status Report on Cell-Based Protein Arrays Retrogenix® Human Protein Library Retrogenix®: The Screen Door of Drug Development Retrogenix® CAR Specificity Testing Charles River Launched New Retrogenix Non-Human Protein Library 

DG Early-Morning Show
Building Matter from the Bottom Up: Dr. Samuel Stupp on Supramolecular Self-Assembly"

DG Early-Morning Show

Play Episode Listen Later Sep 2, 2025 50:13 Transcription Available


In this episode, I talked to Dr. Samuel Stupp, Board of Trustees Professor of Materials Science, Chemistry, and Medicine at Northwestern University. He is one of the pioneers of supramolecular self-assembling materials and is a cofounder of multiple biotech startups, like Amphix Bio, that is working on regenerating spinal cords and tissues using biomaterials. ---------------------------------------------------------------Thanks to the sponsors:Audible: Use my link for a 30-day free trial: http://audibletrial.com/diamondgoatNewsly: https://newsly.mepromo code to receive a 1-month free premium subscription: EARLYMORNING Libysn: https://libsyn.compromo code: DG Dubby Energy: https://www.dubby.ggpromo code for 10% off: DIAMONDGOATOpus Clips:  https://www.opus.pro/?via=diamondgoat----------------------------------------------------------------------------------Listen on:Podcast website: https://www.spreaker.com/podcast/dg-early-morning-show--5943922Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeOPodcast YT channel clips: https://www.youtube.com/@dgearlymorningshowTiktok: @dgearlymorningshowApple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c  Goodpods: https://goodpods.com/podcasts/dg-early-morning-show-211830RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4rBreaker: https://www.breaker.audio/dg-early-morning-showReason: https://reason.fm/podcast/dg-earlymorning-show--------------------------------------Check out my other stuff:Instagram: @itzdiamondgoatTwitter: @lildiamondgoatMain YT channel: youtube.com/diamondgoatTiktok: @lildiamondgoatSoundcloud: @Lil DiamondgoatSpotify: @Lil DiamondgoatMerch store: https://diamondgoat.creator-spring.com

Pharma and BioTech Daily
Pharma and Biotech Daily: Your Quick Update on Pharma and Biotech News

Pharma and BioTech Daily

Play Episode Listen Later Sep 2, 2025 2:00


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ##FDA approves new drug for rare genetic disorderThe FDA has recently approved a new drug for the treatment of a rare genetic disorder. This drug has shown promising results in clinical trials and is expected to provide much-needed relief for patients suffering from this condition. ##Major pharmaceutical company announces mergerA major pharmaceutical company has announced plans to merge with another company in the industry. This merger is expected to create a powerhouse in the pharmaceutical world, with the potential for significant growth and innovation. ##Biotech startup secures funding for groundbreaking researchA biotech startup has recently secured a substantial amount of funding to support their groundbreaking research in a new area of biotechnology. This funding will allow the company to further develop their technology and bring it to market in the near future. ##FDA issues warning about potential side effects of popular medicationThe FDA has issued a warning about potential side effects of a popular medication that is commonly used to treat a variety of conditions. Patients are advised to speak with their healthcare provider if they have any concerns about taking this medication. ##Pharma company announces breakthrough in cancer treatmentA pharmaceutical company has announced a major breakthrough in the treatment of cancer. Their new therapy has shown promising results in clinical trials and has the potential to significantly improve outcomes for cancer patients. ##Biotech firm partners with university on new drug developmentA biotech firm has partnered with a university on a new drug development project. This collaboration brings together the expertise of both organizations to advance research and bring new treatments to market. ##FDA approves expanded use of existing medicationThe FDA has approved the expanded use of an existing medication for the treatment of a different condition. This decision is based on new research showing the effectiveness of this medication in treating this additional condition.

Farm Gate
Wheat from the Chaff: Harvest, biotech and Land Alive

Farm Gate

Play Episode Listen Later Sep 2, 2025 57:57


FFINLO COSTAIN (8point9.com) and JOE STANLEY (GWCT Allerton Project), are joined by TOM PYCRAFT (Ark Summit), who's producing Land Alive at The Dairy Show this October 1st. This time:

Business Of Biotech
Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D.

Business Of Biotech

Play Episode Listen Later Sep 1, 2025 64:36 Transcription Available


We love to hear from our listeners. Send us a message. On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks. Deshpande reflects on his previous experience developing and commercializing Dupixent at Sanofi, describes the history and mechanism of Immediate's glucose-insulin-potassium (GIK) candidate, IMT-358, and explains why there is more to intellectual property than just patents. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Pharma and BioTech Daily
FDA Approves Updated COVID-19 Vaccines Amid Controversy: What You Need to Know

Pharma and BioTech Daily

Play Episode Listen Later Sep 1, 2025 1:15


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Health Secretary Robert F. Kennedy Jr. is set to testify before the Senate Finance Committee on September 4. This comes after the removal of CDC Director Susan Monarez and the appointment of HHS Deputy Secretary Jim O'Neill as her interim replacement. Kennedy, along with FDA Commissioner Marty Makary and CBER Director Vinay Prasad, had previously been vocal against vaccine mandates during the COVID-19 pandemic, citing concerns about limiting medical choice. However, the FDA, under their leadership, has now approved updated COVID-19 vaccines with restrictions that go against this stance.RFK's vaccine restrictions are being viewed as restricting promised medical freedom. The FDA recently gave the green light to updated COVID-19 shots from Pfizer, Moderna, and Novavax but with certain limitations. This news comes as Teva introduces the first GLP-1 generic for obesity to the market, and J&J discontinues its rheumatoid arthritis program after disappointing mid-stage data. Kennedy's upcoming testimony highlights the ongoing turmoil within CDC leadership and raises questions about the conflicting messages surrounding vaccine mandates and medical freedom.

Life-Changing Science: The BioBuilder Podcast
From Classroom to Career: Edwin Gonzalez and his Biotech Journey

Life-Changing Science: The BioBuilder Podcast

Play Episode Listen Later Aug 31, 2025 27:27 Transcription Available


Edwin Gonzalez shares his journey from a BioBuilder apprentice to becoming a lead scientific support specialist at Thermo Fisher by age 23, highlighting how hands-on experiences and mentorship shaped his career path.• Middle school science teacher sparked Edwin's interest in science through engaging projects and supportive environment• First in his family to pursue science, without STEM role models at home• Joined BioBuilder apprenticeship program in 2019 after learning about it from a classmate• Gained first hands-on lab experience learning aseptic technique, pipetting, PCR, and bacterial transformation• Worked on biodesign project to create a device detecting airborne allergens• BioBuilder experience helped him decide to major in biology at Suffolk University• Skills learned at BioBuilder created foundation that made college coursework easier• Landed first industry position at Novo Nordisk through connections from a LabCentral internship• Currently works at Thermo Fisher as a lead scientific support specialist• Role combines lab operations, facilities management and direct research support• Recommends exploring multiple aspects of biology to build a diverse toolkit of experiencesLearn more about BioBuilder's programs for students, educators, and industry professionals here

Alles auf Aktien
KI killt Einsteiger-Jobs und die 7 nächsten Biotech-Blockbuster

Alles auf Aktien

Play Episode Listen Later Aug 29, 2025 20:45


In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über KI-Optimismus bei Dell, eine neue Toniebox-Euphorie in Kinderzimmern und einen Analysten-Push für Siemens. Außerdem geht es um Ulta Beauty, Marvell, Gap, Amazon, Microsoft, Meta, Spotify, IBM, Alphabet, Bristol Myers Squibb, Argenx, Legend Biotech, Summit Therapeutics, Denali Therapeutics, Intellia, Regeneron, Immunocore, Viking Therapeutics, Novo Nordisk und Eli Lilly. Die Tickets zum Finance Summit am 17. September bekommt ihr 40 Euro günstiger – aber nur mit dem exklusiven Code AAA2025, der ihr unter dem folgenden Link eingeben müsst: https://veranstaltung.businessinsider.de/BN5aLV Außerdem könnt ihr unter diesem Link euer Depot hochladen – und mit etwas Glück wird kein Geringerer als Christian W. Röhl euer Depot beim Summit checken und optimieren. https://form.jotform.com/Product_Unit/formular-finance-summit-depot-check Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Pharma and BioTech Daily
Pharma and Biotech Daily: The Latest Updates in the World of Pharmaceuticals and Biotechnology

Pharma and BioTech Daily

Play Episode Listen Later Aug 29, 2025 1:04


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. CDC Director Monarez was fired after less than a month due to internal unrest over new COVID-19 vaccine policies. Novo Nordisk is investing over $500 million in RNA obesity treatments. The FDA has approved updated COVID-19 shots from Pfizer, Moderna, and Novavax with restrictions, causing concern among some groups. Prothena's Alzheimer's drug, PRX012, has shown high rates of brain swelling in Phase I testing. Novo Nordisk is collaborating with other companies on cardiometabolic treatments. The pharma industry is facing challenges and changes, with layoffs and restructurings occurring at various companies. Massachusetts has seen a decline in R&D and biomanufacturing jobs in 2024. Various webinars and events are being held to discuss topics such as pharma manufacturing and data accessibility. Job opportunities in the pharmaceutical industry include positions in business analysis, quality engineering, and project engineering.

AZ Tech Roundtable 2.0
The New Wave of AI-First SaaS Companies Serving SMBs w/ Cooper Simson of Martell Ventures - AZ TRT S06 EP16 (278) 8-24-2025

AZ Tech Roundtable 2.0

Play Episode Listen Later Aug 29, 2025 41:39


The New Wave of AI-First SaaS Companies Serving SMBs w/ Cooper Simson of Martell Ventures - AZ TRT S06 EP16 (278) 8-24-2025       What We Learned This Week: ·         Political & product risk can kill a business overnight. ·         AI is lowering barriers to software creation while eliminating low-value roles. ·         SMBs are ripe for AI adoption, especially in workflow automation & marketing. ·         The best AI businesses solve real problems — not just add shiny features. ·         Future-proofing means building where the “puck” is going, not where it's been.     Guest: Cooper Simson https://www.linkedin.com/in/cooper-simson-896957b1/ Website: https://martellventures.com Contact Cooper -  Instagram: @Coop_Doggy_Dog  Dan Martell's portfolio manager and business partner at Martell Ventures. Cooper talks about what they're building around AI and SaaS software, companies they work with, and the products for SMBs.   Show Notes Guest: Cooper – Entrepreneur & AI Venture Builder Bio ·         Started with a finance degree but never pursued traditional finance. ·         First venture: lead-gen & marketing agency (failed when partner left). ·         Pivoted through freelance work → launched a business helping people apply for government grants using AI. ·         Business collapsed overnight due to political risk when U.S. policy changed. ·         Backed by Dan Martel, who later brought Cooper into Martel Venture Studio AI. ·         Lessons learned: Always maintain control of the product and build businesses that can withstand outside risks.     Segment 1: AI + SMB Software Companies ·         Martel Ventures works with AI-first SaaS companies solving real business problems for SMBs (0–100 employees, $1M–$50M+ in revenue). ·         Examples of portfolio companies: o    Precision Connect – cleans and organizes business data dashboards. o    Atlas AI – AI voice agent that can call leads, nearly indistinguishable from a human caller. o    Hero – recruitment tool powered by AI. ·         AI is the middleman killer → entry-level tech jobs (SDRs, data analysts) most at risk. ·         Core question for any AI product: Does it solve a real problem, or is it just an AI feature? Segment 2: Dan Martel & Martel Ventures ·         Dan Martel: 27+ years in tech, 3 major software exits, 5M+ followers. ·         Founder of SaaS Academy (coached 6,000+ students). ·         Author of Buy Back Your Time. ·         Martel Ventures (founded 2024): o    Invests in and advises AI SaaS startups. o    Target: 10–12 portfolio companies per year. o    Provides equity, funding, and advisory services to accelerate growth & marketing. ·         Martel Ventures' niche: AI + SaaS companies with clear use cases and revenue potential. ·         Cooper's biggest takeaway: “Skate to where the puck is going” — build for future AI demand, not yesterday's. Segment 3: The AI Shift in Business ·         Cost transformation: AI drastically reduces software development and coding costs. ·         AI enables SMBs to: o    Automate workflows & reduce repetitive tasks. o    Boost employee efficiency → turns “C players” into “B+ players.” o    Increase ROI per employee by shifting them to higher-value work. ·         SMB Examples: Local service providers, agencies, or firms generating $1M–$50M annually with 5–200 employees. ·         Key insight: If you can't identify the customer and the problem solved in 5 seconds, the product likely won't succeed. AI Use Cases in Marketing & Ops ·         Lead research automation. ·         Retargeting: AI can read your website, identify IPs, and find who visited. ·         Ad research: analyze competitor ads with AI agents. ·         Campaign automation: compresses timelines from weeks to days. ·         Contact management: AI can segment and organize lists for sharper targeting. Cooper Philosophy: Frameworks & Systems ·  The "Founding 50" framework walkthrough ·  How to diagnose bottlenecks and build fast paths to MRR ·  Distribution engine strategies that accelerate growth Contrarian Takes ·  "Distribution beats capital — especially when your offer hits" ·  Why founders waste time perfecting products instead of selling ·  Red flags he spots instantly in founders AI Market Insights ·  What makes AI-first companies different from traditional SaaS ·  Why SMBs are the sweet spot for AI products right now ·  How venture landscape is changing for AI companies Leadership & Scaling ·  "Lighthouse, not tugboat" guidance approach ·  Speed over perfection in execution ·  People-first, action-oriented leadership style     Dan Martell – Bio info https://www.danmartell.com/ventures/ https://www.linkedin.com/in/dmartell/?originalSubdomain=ca https://www.saasacademy.com/author-dan-martell Dan Martell is a renowned coach and founder of SaaS Academy, celebrated for his expertise in scaling B2B SaaS businesses and significant contributions as an angel investor. Dan Martell is a Canadian entrepreneur, angel investor, and coach known for his expertise in the SaaS (Software as a Service) industry. He's founded, scaled, and successfully exited three technology companies. He's also a prominent figure in the SaaS coaching space, having founded SaaS Academy. Additionally, Martell is an Ironman athlete, philanthropist, and author.  Book – Buy Back Your Time     Biotech Shows: https://brt-show.libsyn.com/category/Biotech-Life+Sciences-Science   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023   Tech Topic: https://brt-show.libsyn.com/category/Tech-Startup-VC-Cybersecurity-Energy-Science  Best of Tech: https://brt-show.libsyn.com/size/5/?search=best+of+tech   ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.  

Biz Today
From the lab to the world: China's biotech rising

Biz Today

Play Episode Listen Later Aug 29, 2025 27:00


China unveils a national policy to accelerate the development and application of artificial Intelligence. How will it reshape the economy, people's lives, and the global landscape of innovation (00:45)?China is doubling down on the biotech industry. In the first half of the year, Chinese drug developers signed over 140 deals with foreign pharmaceutical companies, accounting for one-third of all global agreements. Why is biotech an emerging strategic industry in China? Will China become a biotech powerhouse (17:46)?

Smart Biotech Scientist | Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists
184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho - Part 2

Smart Biotech Scientist | Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

Play Episode Listen Later Aug 28, 2025 17:37


What's the secret to turning a cutting-edge scientific breakthrough into a commercial biotech success?For every inspiring lab discovery, countless prototypes stall before ever reaching the market. The barriers? Securing the right beta testers, outmanoeuvring industry giants, and building teams who understand not just the science, but the user experience from bench to bedside.In this episode of the Smart Biotech Scientist Podcast, David Brühlmann welcomes Chervee Ho, CEO & Co-Founder of BioChromatographix International. Chervee isn't just developing breakthrough column technologies - she's navigating the trenches of commercialization, from resource-stretched startups to partnering with risk-averse manufacturers. With hands-on experience turning innovative science into robust data and real-world adoption, Chervee shares candid lessons from her journey building a biotech company from the ground up.Here are three reasons you can't miss this episode:From Lab Bench to Market: Learn why finding the right beta testing partner is less about luck and more about networking, shared goals, and mutual resource investment - and why a methodical, step-by-step approach beats wishful thinking every time.Winning Against the Big Players: Discover how niche focus, third-party validation, and scientific partnership allow startups like BioChromatographix International to carve out space - even when competing against chromatography industry giants.The Human Factor: Chervee reveals why startup success is all about mindset - resilience, adaptability, and startup “muscle” - far more than specific credentials. If you want to build a team ready for the marathon of commercialization, don't miss these culture insights.Ready to level up your biotech commercialization strategy? Tune in and hear how to accelerate your technology from concept to clinic - without losing focus, funds, or your sanity.Connect with Chervee Ho:LinkedIn: www.linkedin.com/in/cherveehoWebsite: www.biochromatographix.comNext step:Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Pharma and BioTech Daily
Pharma and Biotech Daily: Cutting Through the Noise in the Ever-Evolving Industry

Pharma and BioTech Daily

Play Episode Listen Later Aug 28, 2025 1:25


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Regeneron's experimental drug for myasthenia gravis, cemdisiran, has shown promising results in a Phase III trial and the company is aiming to file for FDA approval by 2026. Pharmaceutical spending in China has reached record levels, with more than $48 billion spent in the first half of the year. Former FDA Commissioner Scott Gottlieb has raised concerns about the US losing its edge in biopharma innovation to China. Additionally, a drug program for a rare neurodegenerative disorder has been discontinued by Amylyx, while pharma companies are increasingly focusing on scientific research and partnerships. Lilly's obesity pill is heading to the FDA for approval, AbbVie is investing in psychedelics, and HHS has announced more changes in the industry. The pharmaceutical landscape is rapidly evolving with new developments and challenges arising.Pharma CEOs are facing increasing pressure amid political turmoil and public distrust over drug pricing. The industry spent over $48 billion in China in the first half of the year, with expectations of increased deal volume in the future. Legal experts are working to determine ownership rights of AI creations in biotech. Obesity treatments are being compared for effectiveness, while biotech companies are making strides in AI-driven manufacturing. Job opportunities in gene therapy and biostatistics are available.

Bio from the Bayou
Episode 101: Biotech Strategy and Creative Fundraising for Rare Disease Drug Development

Bio from the Bayou

Play Episode Listen Later Aug 27, 2025


How can biotech leaders navigate the complexities of neurodegenerative research while tackling today's funding challenges? In this episode, host Elaine Hamm, PhD, welcomes Vikas Sharma, PhD, Chief Business Officer at QurAlis, for an insightful conversation on innovation, leadership, and fundraising in the biotech sector. Drawing from his extensive experience with ALS and neurodegeneration research, Vikas shares lessons on balancing science with business, navigating board dynamics, and finding creative approaches to raise capital. In this episode, you'll discover: Why genetic insights are reshaping neurodegenerative research. How to creatively approach funding when investors are focused on lower-risk, later-stage opportunities. Practical strategies for balancing science, investors, and board relationships to drive biotech success. Tune in to gain actionable strategies and leadership lessons that can help you move your biotech forward with confidence. Links: Connect with Vikas Sharma, PhD, and check out QurAlis. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Connect with Jason Adair, MBA, and Kevin Eggan, PhD. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Pharma and BioTech Daily
Innovations and Opportunities in Pharma and Biotech: A Daily Update

Pharma and BioTech Daily

Play Episode Listen Later Aug 27, 2025 0:46


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Lilly's new oral obesity drug is progressing towards FDA approval in 2025 after positive results from the second phase III trial for Orfoglipron. Analysts are optimistic about the potential for a "double-digit billion dollar opportunity" due to a manufacturing advantage.Arginex is looking to expand the label for Vyvgart in myasthenia gravis, while drugmakers are seeing success in AI-driven manufacturing. The White House has denied rumors of a potential ban on COVID-19 vaccines, as the pharmaceutical industry continues to innovate and adapt to challenges.With ongoing developments in scientific research and drug development, the industry remains at the forefront of innovation.

OffScrip with Matthew Zachary
LEAD EP4: The Long Haul

OffScrip with Matthew Zachary

Play Episode Listen Later Aug 26, 2025 19:10


The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

All Sides with Ann Fisher Podcast
Tech Tuesday: Biotech in Columbus

All Sides with Ann Fisher Podcast

Play Episode Listen Later Aug 26, 2025 50:43


Ohio is home to a multi-billion-dollar biotech industry. It's a growing sector that already employs more than 60,000 people and pays them above-average salaries. We'll be taking a deeper dive into biotech in Ohio.

BioCentury This Week
Ep. 317 - Biotech IPOs, FDA-Stealth & Patent Threat

BioCentury This Week

Play Episode Listen Later Aug 26, 2025 24:12 Transcription Available


There's been a rare IPO filing on NASDAQ as LB Pharma looks to test the market during a year that has seen little activity among U.S. biotechs even as green shoots continue to appear on the Hong Kong stock exchange. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the market for biotech IPOs on NASDAQ and in Hong Kong.The analysts then assess FDA's about-face on Stealth BioTherapeutics' Barth syndrome therapy, putting the decision in the context of a changing regulatory agency; and a BioCentury Guest Commentary that argues that the university-industry engine that drives U.S. innovation is under attack. Also mentioned on this week's podcast: BioCentury's 33rd Back to School package, which reimagines FDA; the upcoming 12th China Healthcare Summit in Shanghai; the evolution of dealmaking in China; and Annalisa Jenkins' take on MHRA and the U.K. biotech ecosystem on The BioCentury Show.View full story: https://www.biocentury.com/article/656849#Biotech #IPO #Pharma #FDA #RareDisease #Biopharma #DrugDevelopment #HealthcareInnovation #HongKongIPO00:00 - Introduction 02:48 – LB Pharma Tests IPO Market07:01 – Hong Kong IPO Momentum09:53 – China Summit Preview13:40 – FDA Reversal on Stealth Bio18:15 – Bayh-Dole Clash & Innovation ThreatsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Smart Biotech Scientist | Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists
183: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho - Part 1

Smart Biotech Scientist | Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

Play Episode Listen Later Aug 26, 2025 24:27


Every year, cutting-edge biomedical technologies are left stranded in the lab, not for lack of innovation, but because they miss the crucial leap from technical performance to genuine industry adoption. The gap between scientific brilliance and commercial success is deceptively simple: deeply understanding and building for your customer's real-world pain points.In this episode, David Brühlmann welcomes Chervee Ho, CEO & Co-Founder of BioChromatographix International. With a background at the intersection of biotechnology and commercial strategy, Chervee has helped reshape how startups approach product development to actually get adopted in conservative markets. From her early days in biotech to launching Singapore's next-generation monolithic chromatography company, Chervee advocates for honest conversations, real customer feedback, and an unflinching commitment to building solutions that people want - not just what scientists think they need.Here are three reasons you can't afford to miss this conversation:Commercial Thinking from Day One: Technical superiority is just the start; Chervee reveals how embedding commercial strategy from the earliest stages, long before the product is ‘perfect', ensures your innovation will actually be used. Start with end-user needs and map backward.Designing for Adoption, Not Just Performance: Don't fall in love with your tech. Discover how BioChromatographix adopted a customer-centric “design for adoption” approach, integrating products into current workflows, minimizing disruption, and collecting real-life feedback that shaped commercial-ready solutions.Bridging the Science-to-Market Divide: Learn how continuous customer engagement, ruthless validation of pain points, and smart use of public data (even while protecting IP) can transform a great idea into a market-ready, trust-building product.Ready to close the gap between invention and adoption? Tune in to discover why commercial thinking isn't just for the sales team and how it's the secret weapon for any biotech scientist wanting to make a lasting impact.Don't just innovate - get your technology into the hands of those who need it most.Connect with Chervee Ho:LinkedIn: www.linkedin.com/in/cherveehoWebsite: www.biochromatographix.comNext step:Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

All Sides with Ann Fisher
Tech Tuesday: Biotech in Columbus

All Sides with Ann Fisher

Play Episode Listen Later Aug 26, 2025 50:43


Ohio is home to a multi-billion-dollar biotech industry. It's a growing sector that already employs more than 60,000 people and pays them above-average salaries. We'll be taking a deeper dive into biotech in Ohio.

Alexander Garrett
OneLegUpAlex Garrett visits with BioTech Exec Quang X. Pham About Having One Leg UP As The Underdog 8-26-25

Alexander Garrett

Play Episode Listen Later Aug 26, 2025 35:39 Transcription Available


Find out more about Quang X. Pham: https://quangxpham.com/. Thanks to Quang for joining OneLegUpAlex Garrett! 

WRAL Daily Download
Genentech becomes the latest biotech company to invest in Holly Springs

WRAL Daily Download

Play Episode Listen Later Aug 26, 2025 8:56


Biotechnology company Genentech broke ground on its first east coast facility on Monday. It plans to hire 420 people in Holly Springs as it works on developing obesity drugs. WRAL's Shaun Gallagher explains what the company's plans are over the next five years.

Pharma and BioTech Daily
Pharma and Biotech Daily: AbbVie Acquires Gilgamesh, IPO Stalemate Ends, Oral Obesity Therapies Disappoint

Pharma and BioTech Daily

Play Episode Listen Later Aug 26, 2025 1:16


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Gilgamesh Pharmaceuticals for $1.2 billion, focusing on neurology and depression treatments. This move follows AbbVie's previous failure with Emraclidine in schizophrenia treatment. The biotech industry's IPO stalemate appears to be ending, with Lb Pharma planning an IPO to fund a phase III-ready schizophrenia asset. The FDA has pulled Valneva's chikungunya shot from the market due to safety concerns, and several obesity drugs have failed to make it to market. Meanwhile, Arnatar is working on advancing RNA therapies beyond silencing.In other news, the disappointment of oral obesity therapies is discussed, with Novo emerging as a leader in the field. Trials for Eli Lilly's Orforglipron and Viking Therapeutics' VK2735 were underwhelming, leading to increased interest in weight loss pills in low- and middle-income countries. Capricor Therapeutics plans to fight FDA rejection of its DMD cardiomyopathy treatment, while a study in JAMA contradicts claims of corruption in vaccine advisory committees. Updates on cancer, cell and gene therapy are also provided.Stay tuned for more updates and feel free to suggest topics for future coverage.

Business Of Biotech
Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D.

Business Of Biotech

Play Episode Listen Later Aug 25, 2025 52:07 Transcription Available


We love to hear from our listeners. Send us a message. On this week's episode, ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa Cmiljanovic, Ph.D. (and COO at Swiss Rockets), losing his company to a hostile takeover, buying the company back, and building out Swiss Rockets as an incubator with manufacturing capabilities and shared scientific expertise. Swiss Rockets' portfolio of companies is developing radioligand therapies, vaccines, and cancer treatments, including bimiralisib for actinic keratosis. Cmiljanovic also discusses U.S. expansion plans, partnering, and funding strategies for early-stage companies.       Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Crime Alert with Nancy Grace
Biotech Exec Knocked Out By Suspect Uber Driver Who was Allergic to His Service Dog | Crime Alert 08.25.25

Crime Alert with Nancy Grace

Play Episode Listen Later Aug 25, 2025 5:45 Transcription Available


A Charleston biotech CEO is knocked unconscious in a parking lot after an Uber driver headbutts and punches him during a dispute over a service dog. California’s serial butt sniffer is arrested again, this time accused of harassing a woman at a Walgreens in Burbank. Drew Nelson reports.See omnystudio.com/listener for privacy information.

Edge of NFT Podcast
Bridging Chains & Shaping Web3: Coinbase, BOB & MOCA at EthCC

Edge of NFT Podcast

Play Episode Listen Later Aug 20, 2025 55:25


Join us for an exciting episode of The Alexei ZamyatinEdge of Show, live from ECC 8 in Cannes! In this episode, Tom Vieira from Coinbase explores how Coinbase is approaching on-chain identity and infrastructure, and why developer experience is at the heart of crypto's next growth cycle. Next Alexei Zamyatin from BOB breaks down Bitcoin-secured rollups, explaining how BOB is merging the strengths of Bitcoin and Ethereum to create a hybrid ecosystem and finally Kenneth Shek from Moca Network shares how Museum of Crypto Art is evolving as a cultural hub, curating digital art and expanding the role of creators in the decentralized era.Don't miss this insightful conversation packed with expert perspectives on the future of Bitcoin, DeFi, and the broader crypto ecosystem!Support us through our Sponsors! ☕

OffScrip with Matthew Zachary
LEAD EP3: Fraying at the Edges

OffScrip with Matthew Zachary

Play Episode Listen Later Aug 19, 2025 22:32


The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.